| Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. |
|
Crit Rev Oncol Hematol |
Myelodysplastic Syndromes (MDS) |
| Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age |
|
Blood Reviews |
Myelodysplastic Syndromes (MDS) |
| Progress in medical therapy in aplastic anemia: why it took so long? |
|
International Journal of Hematology |
Aplastic Anemia |
| Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
|
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Prophylaxis and management of thromboembolism in pnh patients: an italian survey |
|
Annals of Hematology & Oncology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Quality of life after immune suppressive therapy in aplastic anemia |
|
Annals of Hematology |
Aplastic Anemia |
| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
